Transitional Drugs 5
NHS Wales Shared Services Partnership (hosted by Velindre University NHS Trust)contractFind a Tender ↗Ref ocds-h6vhtk-05a8e6Procurement Act 2023SME suitablepending
Estimated value
—
Awarded value
£5.6m
Awarded 25 Nov 2025
Suppliers
3
Lots
1
1 awarded
Published
08 Dec 2025
Description
The provision of drugs that have recently lost exclusivity, namely Aflibercept; Dapagliflozin; Golimumab
Scope
- Reference
- PHA-FTS-60744
- Commercial tool
- Standalone contract
- Contract dates
- 01 Jan 2026 to 31 Dec 2027Possible extension to 31 Dec 2028
12 month extension option available
- CPV classifications
- 33600000
- Contract locations
- Wales, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Product Quality/Acceptability | Pass/Fail | quality | 1.00% |
| Financial (overall cost of contract) | Weighting: 85 | cost | 2.00% |
| Enviromental/Social Value/Community Benefits | Weighting: 15 | quality | 3.00% |
Submission & procedure
- Procedure
- Open procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£5.6m
Award date
25 Nov 2025
Contract start
01 Jan 2026
Contract end
31 Dec 2027